Economic Evaluation of Clopidogrel in Acute Coronary Syndrome Patients without ST-Segment Elevation in Greece

作者: Georgia Kourlaba , Vassilis Fragoulakis , Nikos Maniadakis

DOI: 10.2165/11633820-000000000-00000

关键词: AspirinClopidogrelMyocardial infarctionMedicineST segmentUnstable anginaCardiologyAcute coronary syndromePrasugrelInternal medicineAngina

摘要: Background: Current guidelines recommend treatment with antiplatelet and anticoagulant therapy for the secondary prevention of atherothrombotic events among patients non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina (UA). The CURE (Clopidogrel in Unstable to prevent Recurrent Events) trial has shown that clopidogrel alone combination aspirin is more effective reducing risk than NSTEMI UA patients. However, current climate financial constraints, effectiveness a should be considered conjunction its long-term economic costs determine best possible care.

参考文章(33)
Mark J Sculpher, Karl Claxton, Andrew Briggs, Decision Modelling for Health Economic Evaluation ,(2006)
Christos Pitsavos, , Demosthenes B Panagiotakos, Antonis Antonoulas, Spyros Zombolos, Yannis Kogias, Yannis Mantas, Peter Stravopodis, Georgia Kourlaba, Christodoulos Stefanadis, Epidemiology of acute coronary syndromes in a Mediterranean country; aims, design and baseline characteristics of the Greek study of acute coronary syndromes (GREECS). BMC Public Health. ,vol. 5, pp. 23- 23 ,(2005) , 10.1186/1471-2458-5-23
John L. Moran, Patricia J. Solomon, Aaron R. Peisach, Jeffrey Martin, New models for old questions: generalized linear models for cost prediction Journal of Evaluation in Clinical Practice. ,vol. 13, pp. 381- 389 ,(2007) , 10.1111/J.1365-2753.2006.00711.X
Mark A. Munger, David W. Hawkins, Atherothrombosis: Epidemiology, pathophysiology, and prevention Journal of The American Pharmacists Association. ,vol. 44, ,(2004) , 10.1331/154434504322904569
Hans-Georg Eichler, Sheldon X. Kong, William C. Gerth, Panagiotis Mavros, Bengt Jönsson, Use of Cost‐Effectiveness Analysis in Health‐Care Resource Allocation Decision‐Making: How Are Cost‐Effectiveness Thresholds Expected to Emerge? Value in Health. ,vol. 7, pp. 518- 528 ,(2004) , 10.1111/J.1524-4733.2004.75003.X
Katherine A Lyseng-Williamson, Greg L Plosker, Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. PharmacoEconomics. ,vol. 24, pp. 709- 726 ,(2006) , 10.2165/00019053-200624070-00009
J. Karnon, A. Bakhai, A. Brennan, A. Pandor, M. Flather, E. Warren, D. Gray, R. Akehurst, A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. International Journal of Cardiology. ,vol. 109, pp. 307- 316 ,(2006) , 10.1016/J.IJCARD.2005.06.026